Redevelopment of a former mall, the replacement of a freeway, more hotel rooms and housing are all on the table for ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $997.00. Discover outperforming stocks and ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...

And management's forecast for 2025 sales implies continued 32% growth throughout this new year. That's hardly bad news for Eli Lilly. In fact, the company is forecasting about $1 billion more ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... as the Federal Reserve cuts interest rates and the new administration under Donald Trump pushes for fewer ...

Eli Lilly and Company (LLY) is a global leader in healthcare ... indicating a potential upside of 25.7% from the current levels. With headquarters in the heart of Chicago's financial district ...